Actively Recruiting
A Community Population Screening Cohort Study Based on Polygene Methylation Detection for Colorectal Cancer in Yangzhou
Led by Singlera Genomics Inc. · Updated on 2023-08-29
80000
Participants Needed
2
Research Sites
260 weeks
Total Duration
On this page
Sponsors
S
Singlera Genomics Inc.
Lead Sponsor
N
Northern Jiangsu People's Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a cross-sectional cohort study based on community population jointly developed by Northern Jiangsu People's Hospital and Shanghai Kunyuan Biological Technology Co., LTD. This study will verify the real world results of polygene methylation detection of colorectal cancer in a large prospective cohort of community population, which is expected to enroll 80,000 permanent residents in Yangzhou city. The preliminary design period of the study is 5 years. In this study, questionnaire survey and polygene methylation test of colorectal cancer were used as the primary screening method, and colonoscopy was used as the further validation examination method to screen colorectal cancer and precancerous lesions. The diagnosis and outcome of all lesions were based on colonoscopy and pathological examination. The evaluation indexes include sensitivity, specificity, detection rate of precancerous lesions and adenoma.
CONDITIONS
Official Title
A Community Population Screening Cohort Study Based on Polygene Methylation Detection for Colorectal Cancer in Yangzhou
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Permanent resident population of Yangzhou
- Age between 40 and 74 years, including both ages
- Full ability to understand and participate
- Willing to complete colorectal cancer risk questionnaire and telephone follow-up
- Agree to report tumor diagnosis information promptly during the study
- Able and willing to sign informed consent
You will not qualify if you...
- History of colorectal cancer or other malignant tumors
- Previous colorectal surgery
- Currently receiving any cancer-related treatment
- Major surgery, blood transfusion, or transplantation within the past 3 months
- Participation in other interventional clinical trials within the past 3 months
- Pregnant or lactating women
- Autoimmune diseases, genetic diseases, mental disabilities, or other conditions deemed unsuitable by the researcher
- Poor compliance or inability to complete the study as judged by the researcher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Northern Jiangsu People's Hospital
Yangzhou, Jiangsu, China, 201299
Actively Recruiting
2
Yangzhou First People's Hospital
Yangzhou, Jiangsu, China, 225007
Actively Recruiting
Research Team
L
Liu Jun, Master
CONTACT
L
Liu Rui, Doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here